RESUMEN
Ten patients (6 to 27 years of age) who had severe pancreatic exocrine insufficiency due to cystic fibrosis were studied to determine whether cimetidine would improve dietary fat and nitrogen absorption. When a constant diet was consumed and oral pancreatic enzymes were administered, the addition of cimetidine (150 or 200 mg taken orally one-half hour before meals) signficantly reduced fecal fat excretion from 25.3 +/- 2.9 to 17.3 +/- 2.1 gm/24 hours and fecal nitrogen excretion from 4.5 +/- 0.6 to 3.4 +/- 0.5 gm/24 hours (P less than 0.05). Lower doses of cimetidine resulted in less significant reductions of steatorrhea and azotorrhea. Cimetidine may be a useful adjunct to oral pancreatic enzyme therapy in patients with cystic fibrosis who continue to have steatorrhea and azotorrhea with enzyme therapy alone.
Asunto(s)
Cimetidina/uso terapéutico , Fibrosis Quística/complicaciones , Guanidinas/uso terapéutico , Síndromes de Malabsorción/tratamiento farmacológico , Adolescente , Adulto , Enfermedad Celíaca/tratamiento farmacológico , Enfermedad Celíaca/etiología , Niño , Cimetidina/sangre , Fibrosis Quística/sangre , Quimioterapia Combinada , Femenino , Humanos , Síndromes de Malabsorción/sangre , Síndromes de Malabsorción/etiología , Masculino , Extractos Pancreáticos/uso terapéutico , Pancreatina/uso terapéuticoRESUMEN
Insulin and glucagon secretions were studied during oral glucose tolerance testing and arginine infusion in 13 patients with cystic fibrosis. Two groups of patients were identified; Group I (N=6) whose OGTT was entirely normal and Group II (N=7) who had some abnormality in glucose during OGTT. In each group basal glucagon concentrations were normal and supressed appropriately (p less than 0.05) after glucose; insulin responses were attenuated and the peak responses delayed. During arginine stimulation, insulin secretion was impaired in each group. However, glucagon secretion was diminished only in Group II. Thus, insulinopenia was found in both groups and hyperglucagonemia was not found as a contributory factor to the hyperglycemia in Group II.
Asunto(s)
Fibrosis Quística/fisiopatología , Islotes Pancreáticos/fisiopatología , Adolescente , Adulto , Arginina , Niño , Fibrosis Quística/complicaciones , Femenino , Glucagón/metabolismo , Prueba de Tolerancia a la Glucosa , Humanos , Insulina/metabolismo , Secreción de Insulina , Masculino , Estado Prediabético/complicacionesRESUMEN
The absorption of digoxin in cystic fibrosis was evaluated in 16 subjects by assessing the relationship between dosage expressed in mug/kg/day and serum digoxin concentration. The results indicate that the same relationship exists between maintenance dosage and serum levels in these patients and in patients without cystic fibrosis. Thus, no evidence of impaired absorption was found.